Brief: WntResearch: Updates on on-going phase 1b study of Foxy-5

Opsy Holding AB

24/11/2016 13:07

Nov 24 (Reuters) - WntResearch AB  WNT.ST : 
    * Announces positive results from on-going phase 1b study of drug candidate 
Foxy-5  
    * Says dose level generating gene expression changes in cancer tissue 
samples from treated patients has been identified, suggesting co has reached 
dose of Foxy-5 that exerts biological effects in patients 
    * After negotiations with Swedish Medical Products Agency, design of 
upcoming phase 2 study has been modified - fewer patients will need to be 
included in study and observation time is shortened 
 
     
 Source text: http://bit.ly/2gkJKtC 
     
 Further company coverage:  WNT.ST   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))